Sanofi has halted all clinical trials and cancelled plans to seek regulatory approval of fedratinib, a drug in late-stage development against rare bone marrow cancers, due to safety concerns. The decision follows recent reports of cases consistent with the neurological disorder Wernicke’s encephalopathy in patients in the fedratinib trials, the French drugs group said in a statement on Monday. Fedratinib is a so-called JAK2 inhibitor medicine that was in final Phase III tests for treating myelofibrosis, a rare cancer of the bone marrow.
Help employers find you! Check out all the jobs and post your resume.
